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Management of right ventricular 
outfl ow tract obstruction: 
Evolution to revolution
dren die in early infancy and the remainder die at a mean age of 
12.3 years.(5,6) The advent of the Blalock shunt in the mid 1940s 
gave rise to the first palliative procedures in these children. This led 
to improved survival, but actuarial survival after 25 years in patients 
with all forms of palliative systemic to pulmonary artery shunts was 
in the region of 50% and quality of life was considered limited in 
67% of these.(7) A new era was initiated when Lillehei performed 
the first successful ToF repair in 1954.(8) 
RVOTO following initial repair presented a significant challenge 
during this period. This gave rise to the widespread use of the trans 
annular patch (TAP) - up to 75% by the 1980s.(9,10) These right 
ventricular outflow tracts dilated markedly over time and gave 
rise to pulmonary regurgitation (PR). PR was initially considered a 
benign condition and clinicians largely ignored it. However, after 
3 - 4 decades, unexpected episodes of cardiac deaths, dysrhyth-
mias and right ventricular dysfunction were observed in these 
patients. Clinicians suddenly realised that PR is anything but an 
innocent condition. 
In the current era emphasis has shifted to reparative surgery in 
early infancy and mortality has decreased too with operative mor-
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INTRODUCTION
Until recently, surgery has been the only definitive treatment for 
the management of right ventricular outflow tract obstruction 
(RVOTO). However, a considerable number of these patients will 
subsequently develop right heart and outflow tract dysfunction 
and will require pulmonary valve replacement (PVR). The intro-
duction of percutaneous pulmonary valve implantation (PPVI) has 
opened up new avenues of treatment for this group of patients. 
PPVI has been proven to be effective and safe with low complica-
tion rates.(1-3) A notable advantage is the avoidance of open-
heart surgery and cardiopulmonary bypass combined with short 
hospital stays.
In order to understand the complexities involved in these con-
ditions, the management of tetralogy of Fallot (ToF) can be 
considered as a classical example of development of RVOTO 
management strategies. The historical progression of management 
needs closer inspection.
EVOLUTION OF TREATMENT FOR TETRALOGY 
OF FALLOT
Tetralogy of Fallot is the most common cyanotic congenital heart 
lesion accounting for 5 - 6% of all congenital heart lesions.(4) Natural 
history studies show that, when left untreated, about half of chil-
Percutaneous pulmonary valves have opened up new 
avenues of treatment in patients requiring pulmonary 
valve replacement. The management of tetralogy of Fallot 
demonstrated the evolution of treatment: from palliative 
care to modern day early complete surgical repair.  Use 
of trans-annular patches to treat right ventricle outfl ow 
obstruction gave rise to signifi cant pulmonary regurgita-
tion. Clinicians considered this a benign condition until, 
three decades later patients started dying unexpectedly. 
Surgical pulmonary valve replacement was the only 
treatment, but these showed dysfunction after some 
years. Clear guidelines for intervention do not exist. 
Current guidelines recommend treatment at upper limits 
of tolerance. Arguments for earlier intervention are 
presented, but none of the guidelines have been scien-
tifi cally validated.  SAHeart 2014;11:12-16
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talities as low as 2%.(11,12) While the risk of surgery has declined, 
TAP is still necessary in some neonates. Current surgical strategies 
aim to minimise the use of the TAP, but early repair regularly 
requires aggressive outflow tract reconstruction in infants with 
significant RVOTO.(13)
EFFECTS OF SIGNIFICANT PR
It is now well established that the haemodynamic substrate con-
sisting of a dilating RVOT with resultant PR after reparative surgery 
in ToF patients is a major determinant of adverse outcomes. 
Although clinically “asymptomatic”, long-term follow-up studies 
show accumulating morbidity and mortality. Studies show that 
excess mortality persist for more than 30 years after surgery with 
mortality ratios ranging from 309% - 714% and is clearly asso-
ciated with the use of a TAP.(14) Sudden cardiac death has been 
reported in up to 6% of patients late after repair and has been 
estimated to occur at a rate of 0.2% per year.(14-18) Dysrhythmias 
are common in patients with PR and consist of atrial tachyarrhyth-
mias in up to 30% and high grade ventricular tachycardias in 
5 -10% of patients.(16,19) Gatzoulis identified a prolonged QRS 
≥180ms as a risk factor for ventricular tachycardia and sudden 
death.(20) Additional problems include cardiac failure and right 
heart dilation in up to 29% of patients with isolated PR.(21) Exercise 
intolerance with reduced oxygen uptake is also common in 
patients with dilated outflow tracts and PR.(19,22)
MANAGEMENT OF PR
Surgical pulmonary valve replacement has been the mainstay of 
treatment for patients with significant PR. Since their introduction 
in the early sixties, homografts have been the gold standard for 
PVR.(23) Several other bioprosthetic valves are used, but still have 
to be proven equivalent to homografts.(24)
However, durability of homografts is not ideal and homograft 
degeneration after 10 years was observed in up to 46% of patients 
older than 10 years at implant; in younger patients degeneration 
was even more common: 65% after 5 years.(25,26) Freedom from 
re-operation varies (see Table I) with rates of 97% at 1 year to 
on average 52% - 70% and 31% after 10 and 15 years, respec-
tively.(24,27-29) It should be pointed out that follow-up in most 
studies was not ideal and more frequent follow-up would likely 
have shortened the event free periods. 
It has been projected that the average patient may thus require 
up to 5 operations during a normal lifespan, each with accumula-
tive morbidity and reduction in life expectancy. As a result, clini-
cians tend to delay surgery as long as possible in order to reduce 
the number of surgeries. This wait and watch strategy has been 
criticised and studies have shown that right ventricular recovery 
after PVR may be compromised.(30)
TIMING OF SURGERY
The ideal timing of PVR remains challenging and controversial. 
Although guidelines for indication of PVR have been proposed, 
indications are vague and ambiguous. The most common are: 
patients becoming symptomatic, increasing exercise intolerance, 
arrhythmias, development of moderate or severe tricuspid valve 
regurgitation, stenosis with right ventricular pressure more than 
60% of systemic and volumetric criteria with right ventricular 
end-diastolic volume (RVEDV) ≥170ml/m2 or systolic volume of 
≥85ml/m2.(19)
LIMITATIONS OF CURRENT CRITERIA FOR PVR
It should be noted that current criteria have not unequivocally 
been validated to prolong life and preserve right ventricular 
function. Exercise capacity, symptoms and the usual echocardi-
ographic assessments have been shown to be inconsistent and do 
not correlate with the degree of right heart dysfunction. Magnetic 
resonance imaging (MRI) remains the gold standard for evalua-
tion of right ventricular volumes.(31) However, studies consist of 
small numbers, include heterogeneous RVOT substrates and 
none assessed effect on life-expectancy. Lee showed that a right 
ventricular end-diastolic cut-off value above 163ml/m2 before 
PVR was unlikely to result in “normalisation” of right ventricular 
end-diastolic volumes.(24) In a meta-analysis of adult and paediatric 
studies, Cheung observed that none of the studies reported 
complete normalisation of the RVEDV.(32) They also noticed that 
TABLE 1: Pulmonary homografts: Freedom from re-intervention
    Freedom from re-intervention (%)
Series Number(n) Published 1 year 5 years 10 years 15 years
Kim 112 2011 97 77 35 
Dearnari 1 095 2003    55 32
Stark 656 1998   84 58 31
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although surgical PVR improved right ventricular volumes, QRS 
duration remained largely unchanged. Interestingly, Frigiola 
reported normalisation of RVEDV when using a relatively aggres-
sive PVR policy in younger patients of right ventricular volumes 
below 150ml/m2.(33) In a recent study consisting of 1 085 patients 
after repair of tetralogy of Fallot, the group with the most favourable 
outcomes had only mildly dilated right ventricles with pulmonary 
annulus z-score <0.5 at the age of final analysis and a RVEDV 
of 101 ± 26ml/m2 indicating that near normal haemodynamic 
volumes are associated with improved survival.(34)
One should also take into account the fact that in patients with 
TAP, the MRI right ventricular volumetric measurements include 
the volume of the dilated RVOT and TAP. Since this is usually 
excised during surgical PVR, an exaggerated impression of im-
provement in right ventricular volumes post-surgery may be 
obtained. Furthermore, published literature only considers the 
upper limits of volumetric tolerance but none have assessed the 
lower limits where electromechanical remodelling becomes 
irreversible. This is an important concept: in patients with pulmo-
nary regurgitation, abnormalities of right ventricular deformation 
indices (strain) were found despite normal global right ventricular 
function on MRI.(35) Furthermore, in a study in elite cyclists a 
disproportionate incidence of dysrhythmias and sudden death was 
described. Electrical dysfunction was ascribed to right ventricular 
dilation that occurred because of the huge volume load on the 
right heart during frequent peak exercise in these athletes. It should 
be noted that the episodes occurred in all athletes in the absence 
of measurable right ventricular dysfunction.(36)
The right ventricle is not an isolated structure: it shares the 
interventricular septum with the left ventricle and current indica-
tions ignore demonstrable left ventricular dysfunction and dys-
synchrony as a result of right heart dilation.(37-39) Puranik showed 
that indexed right and left ventricular end-diastolic volumes 
were consistently higher and biventricular function lower in 
tetralogy patients when compared to patients with PR resulting 
from treatment of pure valvar pulmonary stenosis.(40) They also 
identified RVOT dysfunction resulting from TAP as an important 
additional factor in determining left ventricular volume, function 
and long-term prognosis. Current guidelines generally do not take 
the left ventricle into account.
In summary, waiting for symptoms to appear before revalvulation 
is considered, will not lead to reversibility of right ventricular 
dysfunction. In a recent editorial Geva points out that our ability 
to prognosticate in these patients at present is poor and propose 
more liberal indications for PVR.(41)  It is thus evident that clinicians 
should look at new strategies where long term event free right 
ventricular (RV) function – both mechanical and electrical- is the 
ultimate goal and not any degree of recuperation of size or func-
tion, that still can and probably will be associated with late pre-
mature dysfunction.
NEW STRATEGY OF PVR
Ideal treatment for patients with ToF or conditions with similar 
physiology should consist of PVR with a valved conduit with 
negligible procedural risk, perfect long-term function, absence of 
need for valve replacement and normal life expectancy both in 
quantity and quality. This is the strategy we have adopted for the 
management of atrial septal defects (ASD): at an early age when 
mild right ventricle dilation is observed, the unfavourable natural 
history is predictable and the procedure can be carried out with 
negligible risk combined with excellent long-term results.
Treatment options for PVR have changed dramatically - percuta-
neous valves can now be implanted at low and progressively 
decreasing risk and, for the proper indications, are very competitive 
(compared to surgical conduits).(2,3,42-44) The authors’ current 
speculative strategy is demonstrated in Figure 1. As mentioned, 
progressively dilating right ventricular outflow tracts have been 
shown to be a major risk factor for right and left ventricular 
dysfunction. Implanting a stent in the RVOT would arrest this 
increase in RVOT dimension and provide the substrate for a 
percutaneous valve. With current technology, such a window of 
opportunity presents itself at 8 - 12 years of age before the RVOT 
becomes too dilated for secure stent fixation. An adult sized 
percutaneous valve can subsequently be implanted (aiming for 
z-score 0 - 1). This can over time be followed by additional 
PPVI and/or surgical PVR (if required). The ultimate aim of this 
strategy would be to prolong life expectancy and preserve normal 
right ventricular function by intervention before irreversible right 
ventricular electro-mechanical dysfunction sets in. This brings us 
back to our initial ideal treatment strategy: instead of seeing how 
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FIGURE 1: Evolution of management strategies for 
tetralogy of Fallot
Conceptual schematic of evolution of management strategies: ver-
tical axis represents global right heart function including regurgi-
tation, dilation, failure, electro-mechanical abnormalities, etc. Also 
see text for full description of evolution of  strategies. Blue arrow 
indicates window of opportunity. Yellow diamonds indicate PVR 
with surgical homograft. Solid circles indicate PVR with percutaneous 
valved stent. The solid blue bar indicates stent at 8 - 12 years 
(window of opportunity).
A: Normal individual, B: Natural progression in patients with significant PR: decline in RV 
function with dysrhythmias in second decade of life, C: Revalvulation when symptomatic: 
incomplete improvement, D: Strategy PVR with surgical homografts. Increased morbidity 
and mortality with every re-operation, some but incomplete recovery of right ventricular 
function, E: Strategy with PPVI: intervene earlier after first homograft and follow up with 
PPVI or surgical PVR over time. Intervene sooner, reduce number of surgeries and prolong 
life expectancy whilst preventing decline in RV function, F: Proposed new strategy: stent 
RVOT during window of opportunity before important RVOT dilation due to TAP sets in; 
PPVI early with adult sized valve. Follow up with another PPVI and later surgery. Aim is to 
extend lifespan and maintain RV function to as near “normal” as possible.
RV
 fu
nc
tio
n 
(%
)
Age (years)
100
50
0
0 20 40 60
80
A
F
E
D
C
B
far you can allow the RV to be damaged before compromising 
lifespan and function in a patient, (risking premature deaths in many 
patients as happened with previous guidelines) aim for revalvulation 
as soon as an adult sized valve can be implanted, provided this 
happens at near zero risk and with long lasting valve durability (at 
the risk of underestimating complications of a valved stent in the 
RVOT during long term follow-up).
LIMITATIONS OF THIS STRATEGY
It should be noted that the abovementioned strategy is debat-
able and also unproven at this stage: the outcome of such a strategy 
can only be expected in 3 - 4 decades. Questions that remain 
include: will right ventricular function be preserved, will frequency 
of intervention be decreased and what effect will it have on life 
expectancy? Issues such as longevity of percutaneous pulmonary 
valves, susceptibility to endocarditis, age at intervention and immu-
nological factors that have not yet been adequately answered may 
have an effect on the final outcome.(45)
CONCLUSION
Current indications for PVR are vague and consider only the 
upper limits of tolerance. We must remain critical: as clinicians 
we should not repeat the errors of the late 1980s when we 
assumed that any degree of PR would be well tolerated over a 
lifetime. As such, we must remain critical towards the current 
“guidelines” which have some logical background, but the jury is 
still out on their final long term value. Newer strategies have a 
different long-term aim: preserve right ventricular function and 
prolong lifespan. Good arguments exist to lower intervention 
thresholds. However, these remain unproven.
Declaration: Marc Gewillig is a proctor for Numed, 
Medtronic and Edwards.
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